Filtered By:
Drug: Lovenox

This page shows you your search results in order of date.

Order by Relevance | Date

Total 96 results found since Jan 2013.

Middle Cerebral Artery Dissection: A Report of Two Cases With Treatments and Outcomes
Cureus. 2023 May 29;15(5):e39632. doi: 10.7759/cureus.39632. eCollection 2023 May.ABSTRACTIn the present report, we describe two cases of right-sided M1 segment middle cerebral artery dissection in a 51-year-old Asian female and in a 28-year-old Caucasian male patient with no previous history of ischemic stroke or known intracranial atherosclerosis presenting with acute unilateral headache progressing to severe multifocal hemispheric infarction with nearly complete one-sided motor paralysis. In both patients, a middle cerebral artery dissection was detected on angiography; they were given exclusively medical therapy: patie...
Source: Atherosclerosis - June 30, 2023 Category: Cardiology Authors: Giulio Papiri Stefano Bruni Emanuele Puca Sandro Sanguigni Matteo Marcucci Source Type: research

Risk Of Pump Thrombosis With Once Daily Enoxaparin For Anticoagulation Bridging In Patients With Heartmate III
Most centers bridge patients with Left Ventricular Assist Device (LVAD) with heparin drip to avoid thromboembolic complications including stroke and pump thrombosis based on data from HeartMate II. Because of improved hemocompatibility of third generation HeartMateIII (HM3), particularly the decreased risk of in-pump thrombosis, outpatient treatment dose of low molecule weight heparin (LWMH) like Enoxaparin has been used to bridge to warfarin when the INR is subtherapeutic. Once daily dosing has been used in select patients with higher bleeding risk.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Modar Alom, Gurjaspreet Bhattal, Nitin Kabra, David Rawitscher, Amit Alam, Cesar Guerrero-Miranda, Sandra Carey, Timothy George, Aasim Afzal Tags: 180 Source Type: research

Pediatric Moyamoya Syndrome Secondary to Tuberculous Meningitis: A Case Report
We report the case of a female patient who initially presented at 6 years of age with TBM and developed moyamoya syndrome requiring revascularization surgery. Results She was found to have basilar meningeal enhancement and right basal ganglia infarcts. She was treated with 12 months of antituberculosis therapy and 12 months of enoxaparin and maintained on daily aspirin indefinitely. However, she developed recurrent headaches and transient ischemic attacks and was found to have progressive bilateral moyamoya arteriopathy. At age 11 years, she underwent bilateral pial synangiosis for the treatment of her moyamoya syndrome. ...
Source: Neurology Clinical Practice - January 18, 2023 Category: Neurology Authors: Kappel, A. D., Lehman, L. L., Northam, W. T., See, A. P., Smith, E. R. Tags: Clinical/Scientific Note Source Type: research

Cerebrovascular accident in a child with precursor B-cell acute lymphoblastic leukemia and coronavirus disease 2019: a case report
ConclusionOwing to the link between coronavirus disease 2019 and hematologic cancers with hypercoagulopathy and the tendency of patients with leukemia to have coronavirus disease 2019 complications, children with leukemia as well as suspected coronavirus disease 2019 must be hospitalized to prevent blood clot formation.
Source: Journal of Medical Case Reports - December 6, 2022 Category: General Medicine Source Type: research

Ocular Migraine With Amaurosis Fugax of the Left Eye: A Case Report
Cureus. 2022 Aug 22;14(8):e28272. doi: 10.7759/cureus.28272. eCollection 2022 Aug.ABSTRACTIn amaurosis fugax, there is a sudden loss of vision in one eye. Patients gain their vision after a few minutes. The most common underlying cause is atherosclerosis of the internal carotid artery. Other underlying causes include vasospasm of the internal carotid artery, which leads to hypoperfusion and is seen in vasculitis, ocular migraines, and systemic lupus erythematosus. In this case study, a 44-year-old male with a past medical history of migraine with aura presented to the emergency room with transient vision loss in the left e...
Source: Atherosclerosis - September 26, 2022 Category: Cardiology Authors: Faria Tazin Harendra Kumar Muhammad A Israr Camille Celeste Go Source Type: research

Cerebral venous sinus thrombosis following Russell's viper (Daboia russelii) envenomation: A case report and review of the literature
We report a previously healthy middle-aged Indian female who developed cerebral venous sinus thrombosis preceded by features of disseminated bleeding diathesis following Russell's viper bite. The cerebral venous sinus thrombosis was diagnosed by magnetic resonance imaging. The patient responded well to treatment with antivenom and subcutaneous enoxaparin and had no demonstrable neurological deficits at three months of follow-up.PMID:36041514 | DOI:10.1016/j.toxicon.2022.08.014
Source: Toxicon - August 30, 2022 Category: Toxicology Authors: Ritwik Ghosh Mois és León-Ruiz Dipayan Roy Dinobandhu Naga Sona Singh Sardar Juli án Benito-León Source Type: research

Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence
CONCLUSION AND RELEVANCE: When compared with UFH, enoxaparin was associated with a significant reduction in thrombotic events or mortality among COVID-19 patients. The results need confirmation from randomized controlled trials.PMID:35942505 | DOI:10.1177/10600280221115299
Source: The Annals of Pharmacotherapy - August 9, 2022 Category: Drugs & Pharmacology Authors: Lina H AlLehaibi Mukhtar Alomar Abdulaziz Almulhim Sarah Al-Makki Nazar R Alrwaili Shahad Al-Bassam Semat Alsultan Jenan Al Saeed Mohammad Alsheef Ivo Abraham Ahmad Alamer Source Type: research

Large Middle Cerebral Artery Ischemic Stroke in a Therapeutically Anticoagulated Patient With Severe SARS-CoV-2 Infection
Introduction: Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with hypercoagulability which can predispose infected patients to both arterial and venous thromboembolic complications. Despite therapeutic anticoagulation, there remains a risk of ischemic strokes, which may lead to adverse patient outcomes. Only a few cases are described in the literature regarding SARS-CoV-2 positive patients developing thrombotic ischemic strokes despite therapeutic anticoagulation. Case Report: The following is a case discussion regarding a 71-year-old female with pas...
Source: The Neurologist - July 1, 2022 Category: Neurology Tags: Case Report/Case Series Source Type: research

Concurrent Cerebral, Splenic, and Renal Infarction in a Patient With COVID-19 Infection
Conclusion: In this case, a patient with multiple thrombotic events in the acute phase of COVID-19 infection, the delimitation of the inflammatory state through analytical markers as D-dimer helped to individualize the antithrombotic treatment (full anticoagulation or anticoagulation at intermediate doses plus antiplatelet treatment as used in our patient) and its duration. However, more data are needed to better understand the mechanisms and treatment of stroke in patients with COVID-19 infection.
Source: The Neurologist - May 1, 2022 Category: Neurology Tags: Case Report/Case Series Source Type: research

Coagulation factors XI and XII as possible targets for anticoagulant therapy
In this review, we give an overview over observational and experimental studies supporting factors XI and XII as targets for anticoagulant therapy. The majority of observational studies on FXI report low concentrations of FXI to be protective against ischemic stroke and venous thrombosis. There is also extensive evidence from experimental and animal studies supporting FXI inhibition as a target for anticoagulant therapy, alone or in combination with other antithrombotic treatments. Four Phase 2 clinical trials on patients undergoing total knee arthroplasty showed non-inferiority or superiority of FXI inhibition compared to...
Source: Thrombosis Research - April 23, 2022 Category: Hematology Authors: Karsten Engseth Kluge, Ingebj ørg Seljeflot, Harald Arnesen, Torstein Jensen, Sigrun Halvorsen, Ragnhild Helseth Source Type: research

Case of Venous Thromboembolia Under Enoxaparin Prophylaxis After Recovering From Acute Ischemic Stroke in Consequence of COVID-19-Related MIS-C
No abstract available
Source: The Pediatric Infectious Disease Journal - April 16, 2022 Category: Infectious Diseases Tags: Letters to the Editor Source Type: research

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news